Title |
Tumor homologous recombination deficiency assays: another step closer to clinical application?
|
---|---|
Published in |
Breast Cancer Research, July 2014
|
DOI | 10.1186/s13058-014-0409-7 |
Pubmed ID | |
Authors |
Shane R Stecklein, Priyanka Sharma |
Abstract |
Inherited and acquired defects in homologous recombination, a phenotype termed 'BRCAness', may lend to therapeutic exploitation in breast cancer. To this end, development and clinical evaluation of platforms to identify signatures of BRCAness are of immense interest. In this issue of Breast Cancer Research, Vollebergh and colleagues report that a BRCA-like array comparative genomic hybridization (aCGH) genomic instability signature is associated with benefit from high-dose cyclophosphamide-thiotepa-carboplatin chemotherapy. We discuss the strengths and weaknesses of this study and consider the clinical significance and applicability of this aCGH BRCAness signature in the context of other existing homologous recombination deficiency detection platforms. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 5% |
Germany | 1 | 5% |
Unknown | 20 | 91% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 7 | 32% |
Student > Master | 3 | 14% |
Student > Bachelor | 2 | 9% |
Student > Ph. D. Student | 2 | 9% |
Student > Postgraduate | 2 | 9% |
Other | 4 | 18% |
Unknown | 2 | 9% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 8 | 36% |
Medicine and Dentistry | 6 | 27% |
Biochemistry, Genetics and Molecular Biology | 3 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
Chemical Engineering | 1 | 5% |
Other | 0 | 0% |
Unknown | 3 | 14% |